Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleCLINICAL INVESTIGATIONS

1-11C-Acetate Kinetics of Prostate Cancer

Christiaan Schiepers, Carl K. Hoh, Johan Nuyts, Marc Seltzer, Christine Wu, Sung-Cheng Huang and Magnus Dahlbom
Journal of Nuclear Medicine February 2008, 49 (2) 206-215; DOI: https://doi.org/10.2967/jnumed.107.044453
Christiaan Schiepers
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carl K. Hoh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johan Nuyts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Seltzer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Wu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sung-Cheng Huang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Magnus Dahlbom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • FIGURE 1. 
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1. 

    Kinetic model with 3 compartments and 2 tissues for prostate. CO2 concentration in tissue is low because of low intracellular pH. In our simplified model, intracellularly labeled CO2 (dotted gray box) is considered negligible. Blood-to-tissue transport is minimal as indicated by dotted gray arrow. Most of labeled CO2 is transported rapidly to blood (as part of k2). Metabolic pool consists of precursors for lipids, amino acids, fatty acids, and steroids that trap or retain 11C label. Labeled products of tricarboxylic acid (TCA) cycle also contribute to metabolic pool (as part of k3). Increase in TCA cycle metabolism would lead to increase of both k2 and k3.

  • FIGURE 2. 
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2. 

    Parametric images from 65-y-old man with primary prostate cancer. (A) Factor images representing vascular component; right and left iliac arteries are identified in 6 transverse planes. (B) Maximum-intensity-projection image of factor 1 in anterior–posterior view representing iliac arteries. (C) Transverse factor images representing tumor component. Note bilobular involvement. Arrow points to tracer in rectum. (D) Maximum-intensity-projection image of factor 2 in anterior–posterior view showing prostate. Note hot spot, left and superior of prostate, represents metastatic lymph node.

  • FIGURE 3. 
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3. 

    Time–activity-curves from iliac arteries (squares, solid line), metabolite-corrected input function (open squares, dashed line), and prostate tumor (triangles, dotted line). Uptake is expressed in SUV (standardized uptake value). (A) A 65-y-old man with primary prostate cancer (patient in Fig. 2). (B) A 57-y-old man with recurrent cancer; note lower SUV of tumor. (C) A 49-y-old volunteer with BPH.

  • FIGURE 4. 
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4. 

    Average values of kinetic parameters for 3 subgroups: primary and recurrent cancer as well as BPH. Error bar denotes 1 SD. Primary and recurrent prostate cancer show significant differences (*P < 0.01) for k1 and K (Table 2).

  • FIGURE 5. 
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5. 

    Scatter diagram of transport rate constant k1 vs. influx rate constant K, both in min−1. Triangles indicate primary cancer and open boxes indicate recurrent cancer. Lines are results of linear regression analysis, r = 0.82 (black) and r = 0.84 (gray). Slopes of linear fits are not statistically different.

  • FIGURE 6. 
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 6. 

    Scatter diagram of influx rate constant K in min−1 vs. 1-11C-acetate uptake in prostate (SUV). Black squares indicate primary cancer and open circles indicate recurrent cancer. Lines are results of linear regression analysis, r = 0.91 (squares) and r = −0.17 (circles).

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1

    Kinetic Modeling of Prostate

    Parameter3C-5p3C-5p3C-4p3C-4p3C-3p3C-3p2C-3p2C-3pPatlak-2pPatlak-2p
    Metabolite correctionNoYesNoYesNoYesNoYesNoYes
    n22222222222222222222
    k10.289 ± 0.1300.318 ± 0.1450.301 ± 0.1310.319 ± 0.1420.295 ± 0.1340.316 ± 0.1450.289 ± 0.1320.231 ± 0.099
    k20.190 ± 0.0510.184 ± 0.1080.206 ± 0.0540.216 ± 0.0910.190 ± 0.0470.202 ± 0.1000.177 ± 0.0460.048 ± 0.013
    k30.006 ± 0.0100.126 ± 0.0780.012 ± 0.0180.141 ± 0.0460.005 ± 0.0080.124 ± 0.046
    k40.002 ± 0.0020.008 ± 0.0080.008 ± 0.0170.006 ± 0.004
    K0.006 ± 0.0100.124 ± 0.0620.012 ± 0.0130.124 ± 0.0490.006 ± 0.0080.118 ± 0.0490.005 ± 0.0110.109 ± 0.056
    Vb0.020 ± 0.0200.024 ± 0.0260.001 ± 0.0030.000 ± 0.001
    Vd1.52 ± 0.631.50 ± 1.281.44 ± 0.670.96 ± 0.461.53 ± 0.591.08 ± 1.031.62 ± 0.604.87 ± 1.801.51 ± 0.611.57 ± 1.50
    WRSS397 ± 420295 ± 278439 ± 448376 ± 368491 ± 478372 ± 386491 ± 470852 ± 722
    NF091604Reference M−Reference M+
    AIC71 ± 2865 ± 2672 ± 2868 ± 2874 ± 2866 ± 2875 ± 2792 ± 24
    • 2C, 3C = number of compartments; 2p, 3p, 4p, 5p = number of parameters in model. In model 3C-4p, Vb = 0 and in model 3C-3p both Vb and k4 are fixed to 0. NF = number of studies with a significantly lower error compared with corresponding 2C-3p (M− and M+—i.e., without and with metabolite correction as reference) determined with F test (P < 0.05). AIC (Akaike Information Criterion) is defined in Equation 3, and WRSS was used to calculate the likelihood function (35).

    • Estimates of fitted parameters k1–k4, as well as influx rate constant K, Vb, and Vd. Results are expressed as mean ± 1 SD of 22 studies (n) in 22 patients. Input function was corrected for partial-volume effects with 0.6 as recovery coefficient and for metabolites as indicated. Error estimate WRSS (Eq. 4) is a measure of “goodness of fit” between measured and calculated output function. Graphical analysis with Patlak plots was applied on images between 7 and 20 min.

    • View popup
    TABLE 2

    Three-Compartment, 2-Tissue Model with 3 Parameter Estimates, k1–k3, Influx Rate Constant K, and Distribution Volume Vd

    TypePrimary CancerRecurrent cancerPBPH
    n10102
    k10.419 ± 0.1360.208 ± 0.073<0.0010.339 ± 0.050
    k20.218 ± 0.0740.202 ± 0.124NS0.122 ± 0.066
    k30.120 ± 0.0260.140 ± 0.054NS0.066 ± 0.058
    K0.152 ± 0.0510.086 ± 0.017<0.010.110 ± 0.049
    Vd1.25 ± 0.320.69 ± 0.27<0.0012.19 ± 1.18
    Patlak K0.137 ± 0.0620.079 ± 0.0350.020.121 ± 0.048
    Patlak Vd1.95 ± 1.671.00 ± 1.27NS2.49 ± 1.22
    SUV-early3.80 ± 0.991.83 ± 0.40<0.0013.55 ± 0.60
    SUV-late3.84 ± 1.071.91 ± 0.34<0.0013.35 ± 0.24
    • NS = not significant.

    • Patlak plot results are given, as well. Results are expressed as mean ± 1 SD for 3 different tissue types. 1-11C-Acetate uptake at early (6–10 min) and late (15–20 min) time points is presented in SUVs. P denotes significance level by comparison of primary vs. recurrent cancers.

Additional Files

  • Figures
  • Tables
  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Appendix
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 49 (2)
Journal of Nuclear Medicine
Vol. 49, Issue 2
February 2008
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
1-11C-Acetate Kinetics of Prostate Cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
1-11C-Acetate Kinetics of Prostate Cancer
Christiaan Schiepers, Carl K. Hoh, Johan Nuyts, Marc Seltzer, Christine Wu, Sung-Cheng Huang, Magnus Dahlbom
Journal of Nuclear Medicine Feb 2008, 49 (2) 206-215; DOI: 10.2967/jnumed.107.044453

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
1-11C-Acetate Kinetics of Prostate Cancer
Christiaan Schiepers, Carl K. Hoh, Johan Nuyts, Marc Seltzer, Christine Wu, Sung-Cheng Huang, Magnus Dahlbom
Journal of Nuclear Medicine Feb 2008, 49 (2) 206-215; DOI: 10.2967/jnumed.107.044453
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • DISCUSSION
    • CONCLUSION
    • Footnotes
    • References
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Human Biodistribution and Radiation Dosimetry of 18F-Clofarabine, a PET Probe Targeting the Deoxyribonucleoside Salvage Pathway
  • Evaluation of Prostate Cancer with 11C-Acetate PET/CT
  • Late Imaging with [1-11C]Acetate Improves Detection of Tumor Fatty Acid Synthesis with PET
  • Dynamic PET/CT with 11C-Acetate in Prostate Cancer
  • Reply: Dynamic PET/CT with 11C-Acetate in Prostate Cancer
  • 11C-Acetate PET/CT in Localized Prostate Cancer: A Study with MRI and Histopathologic Correlation
  • Assessment of PET Tracer Uptake in Hormone-Independent and Hormone-Dependent Xenograft Prostate Cancer Mouse Models
  • Kinetics of 3'-Deoxy-3'-18F-Fluorothymidine During Treatment Monitoring of Recurrent High-Grade Glioma
  • Tumor Cell Metabolism Imaging
  • Google Scholar

More in this TOC Section

  • Feasibility of Ultra-Low-Activity 18F-FDG PET/CT Imaging Using a Long–Axial-Field-of-View PET/CT System
  • Cardiac Presynaptic Sympathetic Nervous Function Evaluated by Cardiac PET in Patients with Chronotropic Incompetence Without Heart Failure
  • Validation and Evaluation of a Vendor-Provided Head Motion Correction Algorithm on the uMI Panorama PET/CT System
Show more Clinical Investigations

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire